Freestone Capital Holdings, LLC Vertex Pharmaceuticals Inc Transaction History

Freestone Capital Holdings, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$234.96 - $292.55 $93,279 - $116,142	-397 Reduced 28.1%	1,016 $286,000
Q1 2022 May 12, 2022	SELL	$221.42 - $260.97 $9,521 - $11,221	-43 Reduced 2.95%	1,413 $369,000
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $257,726 - $325,343	1,456 New	1,456 $320,000
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $225,649 - $252,519	-1,244 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $7,124 - $8,401	-38 Reduced 2.96%	1,244 $251,000
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $67,488 - $78,667	326 Added 34.1%	1,282 $275,000
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $48,440 - $64,605	234 Added 32.41%	956 $226 Million
Q3 2020 Nov 06, 2020	BUY	$255.65 - $303.1 $184,579 - $218,838	722 New	722 $196,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

Stay updated on Freestone Capital Holdings, LLC with notifications on news.